Cantargia rapporterar att första patienten behandlats med
Cantargia AB - IPOhub
A new phase Ib clinical trial CAN04, an antibody targeting interleukin 1 receptor accessory protein (IL1RAP), is currently being investigated for treatment of non-small cell lung cancer (NSCLC) and pancreatic cancer (PDAC) in phase IIa clinical development in Europe. The antibody CAN04 binds strongly to the target IL1RAP and functions both though ADCC as well as blocking IL-1α and IL-1β signaling. Thereby, CAN04 can counteract the contribution of the IL-1 system to the immune suppressive tumor microenvironment and development of resistance to chemotherapy. CAN04 is investigated in two clinical trials.
Antikroppen CAN04 binder IL1RAP med hög affinititet och fungerar både genom blockad av IL-1-signalering samt s k Antibody-Dependent Cellular Cytotoxicity (ADCC). Prekliniska data visar att CAN04 kan öka effekten av cellgifter. The antibody drug candidate CAN04 is investigated in combination with two different chemotherapy regimes in a phase IIa clinical trial (CANFOUR) in patients with NSCLC or pancreatic cancer (www.clinicaltrials.gov). During 2018, Cantargia reported positive effects in preclinical studies when CAN04 was combined with the chemotherapy cisplatin. Cantargia AB today announced that the IND application regarding the antibody CAN04 has been approved by the US FDA. CAN04, an antibody targeting interleukin 1 receptor accessory protein (IL1RAP Cantargia AB today announced the submission of a clinical trial application investigating antibody CAN04 in combination with FOLFIRINOX for first line treatment of metastatic pancreatic cancer . future production of the CAN04 antibody.
CANFOUR - RCC - Regionala cancercentrum
FIGS. 4A-C. Ability of exemplary antibody CAN04 to block (4A) IL-1β (4B) IL-1α, and (4C) IL-33 signalling.
Cantargia IND application for CAN04 approved by FDA Placera
The main project, the antibody CAN04, is being studied in the clinical phase I/IIa CANFOUR study with a primary focus on non-small cell lung cancer and pancreatic cancer. The antibody CAN04 binds IL1RAP with high affinity and functions through both ADCC and blockade of IL-1α and IL-1β signaling. CAN04 is investigated in an open label phase I/IIa clinical trial, CAN04 is a first-in-class fully humanized monoclonal antibody targeting IL1RAP, a co-receptor for the IL-1 receptor which is expressed on human cancer cells. CAN04 binds to IL1RAP with high affinity in a manner that blocks signal transduction from IL-1 and IL-33 into the cells. Cantargia has announced that its IND application regarding the antibody CAN04 has been approved by the US FDA. CAN04, an antibody targeting interleukin 1 receptor accessory protein (IL1RAP), is currently being investigated for treatment of non-small cell lung cancer (NSCLC) and pancreatic cancer (PDAC) in phase IIa clinical development. Cantargia’s antibody CAN04 binds IL1RAP with high affinity and functions through both Antibody Dependent Cellular Cytotoxicity and blockade of interleukin 1 signaling.
Antibody-Dependent Cellular Cytotoxicity (ADCC) och
An open label, dose escalation followed by dose expansion, safety and tolerability trial of CAN04, a fully humanized monoclonal antibody against IL1RAP,
för den framtida kommersialiseringen av produktkandidaten CAN04, ett flertal olika former av så kallade antibody-drug conjugates riktade
Cantargia $CANTA reports high response rates with CAN04 combination Cantargia: Presentation of Phase I Clinical Data on Antibody CAN04 at ASCO
CANTARGIA: CAN04 HAR BREDARE ANGREPPSSÄTT ÄN CANAKINUMAB - clinical trial investigating antibody CAN04 and FOLFIRINOX in pancreatic can. The main project, the antibody CAN04, is being studied clinically as combination therapy with chemotherapy or immune therapy with a primary focus on
läkemedelskandidaten CAN04 och bolagets planer. För detaljer kring presentationerna, se nedan. Presentationen på Antibody Engineering
IL1RAP is overexpressed in various solid tumors, both on cancer cells and in the tumor microenvironment. CAN04 is a fully humanized antibody that binds
Cantargia kommer att presentera nya prekliniska data runt antikroppen CAN04 på den vetenskapliga konferensen Antibody Engineering and
Cantargia: CAN04 ASCO 2019 presentation.
Familjepension kostnad
4A-C. Ability of exemplary antibody CAN04 to block (4A) IL-1β (4B) IL-1α, and (4C) IL-33 signalling. FIG. 5. The total cell expansion of primary primitive CML cells in presence of IL1b is significantly reduced with exemplary antibody CAN04 in comparison with both control and a reference antibody.
CAN04 is currently in phase IIa clinical development for non-small cell lung cancer and pancreatic cancer.
Lediga sjuksköterskejobb västra götaland
nedre kungsholmen karta
socialt arbete tvarvetenskapligt
30 min parkering
arbets och organisationspsykologi
Clinical Supply Manager • Cantargia • Lund - Jobbsafari
Cantargia’s antibody CAN04 binds IL1RAP with high affinity and functions through both Antibody Dependent Cellular Cytotoxicity and blockade of interleukin 1 signaling.
Clinical Supply Manager • Cantargia • Lund - Jobbsafari
Mar 9, 2021 The anti-IL-1 beta antibody is still in a couple more pivotal NSCLC studies, Can04, like canakinumab, is also being tested in combination with Nov 26, 2020 CAN10 is fully humanized monoclonal antibody targeting IL1RAP. The main project, the antibody CAN04, is being studied clinically as Aug 15, 2020 CAN04 is a fully humanized antibody that binds IL1RAP with high affinity (Kd = 1.10 pM), disrupts IL1α and IL1β signaling (IC50 = 3.9 and 4.1 nM Cantargia develops antibody based therapy against the target IL1RAP. The lead candidate CAN04 is for treatment of solid tumors and hematoligacal cancers, Feb 10, 2021 The antibody CAN04 binds IL1RAP with high affinity and functions through both blockade of IL-1 signaling and Antibody-Dependent Cellular Rabbit mAbs were isolated using selected lymphocyte antibody method (SLAM) CAN-04-0240 pmid:http://www.ncbi.nlm.nih.gov/pubmed/15289306.
Thereby, CAN04 can counteract the contribution of the IL-1 system to the immune suppressive tumor microenvironment and development of resistance to chemotherapy. CAN04 is investigated in two clinical trials. Cantargia develops antibody-based pharmaceuticals against interleukin-1 receptor accessory protein (IL1RAP). The antibody CAN04 binds IL1RAP with high affinity and functions through both Antibody-Dependent Cellular Cytotoxicity (ADCC) and blockade of IL-1 signaling. STOCKHOLM, Dec. 2, 2019 /PRNewswire/ -- Cantargia AB today announced the first interim data with antibody CAN04 in combination with chemotherapy in the ongoing phase IIa CANFOUR study.